AC IMMUNE SA (ACIU) Fundamental Analysis & Valuation

Q: Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

ChartMill assigns a fundamental rating of 1 / 10 to ACIU.

Q: Can you provide the profitability details for AC IMMUNE SA?

AC IMMUNE SA (ACIU) has a profitability rating of 0 / 10.

NASDAQ:ACIU • CH0329023102

2.98 USD

-0.05 (-1.65%)

At close: May 1, 2026

2.9999 USD

+0.02 (+0.67%)

After Hours: 5/1/2026, 8:08:21 PM

This ACIU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1. ACIU Profitability Analysis

1.1 Basic Checks

In the past year ACIU has reported negative net income.
ACIU had a negative operating cash flow in the past year.
ACIU had negative earnings in each of the past 5 years.
In the past 5 years ACIU reported 4 times negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -45.67%, ACIU perfoms like the industry average, outperforming 49.42% of the companies in the same industry.
Looking at the Return On Equity, with a value of -156.96%, ACIU is doing worse than 65.70% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-45.67%
ROE	-156.96%
ROIC	N/A

ROA(3y)-32.46%

ROA(5y)-32.68%

ROE(3y)-78.69%

ROE(5y)-61.88%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ACIU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA ROE ROIC Operating and Profit Margin Show most profitable peers

2. ACIU Health Analysis

2.1 Basic Checks

ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACIU has more shares outstanding than it did 1 year ago.
ACIU has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ACIU is higher compared to a year ago.

2.2 Solvency

ACIU has an Altman-Z score of -4.11. This is a bad value and indicates that ACIU is not financially healthy and even has some risk of bankruptcy.
ACIU has a Altman-Z score (-4.11) which is in line with its industry peers.
ACIU has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ACIU (0.08) is worse than 62.21% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-4.11

ROIC/WACCN/A

WACC4.93%

2.3 Liquidity

ACIU has a Current Ratio of 1.02. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.02, ACIU is doing worse than 87.02% of the companies in the same industry.
A Quick Ratio of 1.02 indicates that ACIU should not have too much problems paying its short term obligations.
ACIU has a Quick ratio of 1.02. This is amonst the worse of the industry: ACIU underperforms 86.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.02
Quick Ratio	1.02

More info and screens

WACC Debt/Equity How to determine the health of a company Altman-Z score Show peers with great health

3. ACIU Growth Analysis

3.1 Past

ACIU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.69%.
ACIU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.92%.
Measured over the past years, ACIU shows a very negative growth in Revenue. The Revenue has been decreasing by -25.34% on average per year.

EPS 1Y (TTM)-32.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.75%

Revenue 1Y (TTM)-86.92%

Revenue growth 3Y-2.88%

Revenue growth 5Y-25.34%

Sales Q2Q%-70.27%

3.2 Future

The Earnings Per Share is expected to grow by 2.32% on average over the next years.
The Revenue is expected to grow by 92.91% on average over the next years. This is a very strong growth

EPS Next Y18.78%

EPS Next 2Y65.43%

EPS Next 3Y22.22%

EPS Next 5Y2.32%

Revenue Next Year553.48%

Revenue Next 2Y424.59%

Revenue Next 3Y137.09%

Revenue Next 5Y92.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks Show best growing peers

4. ACIU Valuation Analysis

4.1 Price/Earnings Ratio

ACIU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACIU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ACIU's earnings are expected to grow with 22.22% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y65.43%

EPS Next 3Y22.22%

More info and screens

Price/Earnings Price/FCF FCF per share EV/EBITDA PEG RATIO Show best valued peers

5. ACIU Dividend Analysis

5.1 Amount

ACIU does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks Show peers with best dividend

ACIU Fundamentals: All Metrics, Ratios and Statistics

AC IMMUNE SA

NASDAQ:ACIU (5/1/2026, 8:08:21 PM)

After market: 2.9999 +0.02 (+0.67%)

2.98

-0.05 (-1.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Industry StrengthN/A

Industry GrowthN/A

Earnings (Last)04-28 2026-04-28

Earnings (Next)08-03 2026-08-03

Inst Owners26.22%

Inst Owner Change-0.01%

Ins Owners3.75%

Ins Owner Change-0.46%

Market Cap303.27M

Revenue(TTM)3.57M

Net Income(TTM)-70.45M

Analysts88

Price Target9.18 (208.05%)

Short Float %4.64%

Short Ratio10.31

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)21.12%

Min EPS beat(2)17.94%

Max EPS beat(2)24.3%

EPS beat(4)3

Avg EPS beat(4)8.34%

Min EPS beat(4)-18%

Max EPS beat(4)24.3%

EPS beat(8)5

Avg EPS beat(8)-4.96%

EPS beat(12)8

Avg EPS beat(12)-63.29%

EPS beat(16)11

Avg EPS beat(16)-44.54%

Revenue beat(2)1

Avg Revenue beat(2)-28.93%

Min Revenue beat(2)-71.06%

Max Revenue beat(2)13.19%

Revenue beat(4)2

Avg Revenue beat(4)26.78%

Min Revenue beat(4)-71.06%

Max Revenue beat(4)200.32%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-6.9%

EPS NQ rev (1m)12.66%

EPS NQ rev (3m)N/A

EPS NY rev (1m)9.08%

EPS NY rev (3m)20.48%

Revenue NQ rev (1m)-33.33%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)9.71%

Revenue NY rev (3m)-13.7%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	66.66
P/FCF	N/A
P/OCF	N/A
P/B	5.31
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.88

EYN/A

EPS(NY)-0.71

Fwd EYN/A

FCF(TTM)-0.88

FCFYN/A

OCF(TTM)-0.87

OCFYN/A

SpS0.04

BVpS0.56

TBVpS-0.07

PEG (NY)N/A

PEG (5Y)N/A

Graham Number0 (-100%)

Profitability

		Industry Rank	Sector Rank
ROA	-45.67%
ROE	-156.96%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-32.46%

ROA(5y)-32.68%

ROE(3y)-78.69%

ROE(5y)-61.88%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	35.96%
Cap/Sales	25.19%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.02
Quick Ratio	1.02
Altman-Z	-4.11

F-Score1

WACC4.93%

ROIC/WACCN/A

Cap/Depr(3y)32.92%

Cap/Depr(5y)52.17%

Cap/Sales(3y)10.9%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-32.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%18.75%

EPS Next Y18.78%

EPS Next 2Y65.43%

EPS Next 3Y22.22%

EPS Next 5Y2.32%

Revenue 1Y (TTM)-86.92%

Revenue growth 3Y-2.88%

Revenue growth 5Y-25.34%

Sales Q2Q%-70.27%

Revenue Next Year553.48%

Revenue Next 2Y424.59%

Revenue Next 3Y137.09%

Revenue Next 5Y92.91%

EBIT growth 1Y-31.47%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year14.99%

EBIT Next 3Y0.61%

EBIT Next 5Y-0.62%

FCF growth 1Y-207.5%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-205.19%

OCF growth 3YN/A

OCF growth 5YN/A

AC IMMUNE SA / ACIU Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

ChartMill assigns a fundamental rating of 1 / 10 to ACIU.

What is the valuation status of AC IMMUNE SA (ACIU) stock?

ChartMill assigns a valuation rating of 1 / 10 to AC IMMUNE SA (ACIU). This can be considered as Overvalued.

Can you provide the profitability details for AC IMMUNE SA?

AC IMMUNE SA (ACIU) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for ACIU stock?

The Earnings per Share (EPS) of AC IMMUNE SA (ACIU) is expected to grow by 18.78% in the next year.